The Medical Research Commercialisation Fund

General contacts
Investor type

VC

Founded

2007

AUM

-

Location

Louth, New South Wales, Australia

Investment Ticket

$1-5 m

Investment Stage

Series A Seed Series B Late Stage (Series C+)

Region of investment

Australia and others
Investor profile last updated: 13 August, 2026

Profile

The Medical Research Commercialisation Fund is a life sciences investment firm based in Australia and New Zealand. It collaborates with major Australian superannuation funds, CSL, the Australian and New Zealand governments, and over 50 leading medical research institutes and research hospitals. The firm focuses on bridging the gap between medical research and the creation of new medical products, thus enhancing patient outcomes and saving lives. They engage deeply with scientists, clinicians, and entrepreneurs to ensure their investments succeed.

The firm focuses on sectors within life sciences, particularly biotechnology and medical technology, supporting both pre-clinical and clinical stage innovations. Their investment strategy includes participating in various stages such as seed and growth, with a regional focus mainly on Australia and New Zealand. It manages a range of life sciences funds, collaborating closely with governmental and private partners to achieve its goals.

Notable investments within their portfolio include Que Oncology - treatment for hot flashes in cancer survivors, CatalYm - reversing immunosuppression to induce anti-tumor responses, NRG Therapeutics - mitochondrial therapeutics for neurodegenerative disorders, Pheon Therapeutics - ADCs for cancer treatment, and Currus Biologics - CAR-T cell therapies for solid cancers. These investments reflect the firm's commitment to advancing cutting-edge medical and genomics innovations.

Industry

HealthTech MedTech Pharmaceuticals Medical Devices Healthcare Services Biotechnology

Contacts

Name
Title
Email
Social Networks
avatar
Chris Nave Chief Executive Officer
Chief Executive Officer
-
avatar
Erica Bremner Kneipp Director
Director
-
LinkedIn
Upgrade to see contacts
avatar
KP2cgMaVWGI0vXEm KP2cgMaVWGI0vXEm
KP2cgMaVWGI0vXEm
[email protected]
linkedin twitter
avatar
KP2cgMaVWGI0vXEm KP2cgMaVWGI0vXEm
KP2cgMaVWGI0vXEm
[email protected]
linkedin twitter
avatar
KP2cgMaVWGI0vXEm KP2cgMaVWGI0vXEm
KP2cgMaVWGI0vXEm
[email protected]
linkedin twitter
Investment-team contacts for The Medical Research Commercialisation Fund — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about The Medical Research Commercialisation Fund

The Medical Research Commercialisation Fund is a venture capital firm. It backs companies at Series A, Seed, Series B and Late Stage (Series C+), writing tickets of $1-5 m.
The Medical Research Commercialisation Fund is located in Louth, New South Wales, Australia.
The Medical Research Commercialisation Fund was founded in 2007.
The Medical Research Commercialisation Fund invests in companies and startups in HealthTech, MedTech, Pharmaceuticals, Medical Devices, Healthcare Services, Biotechnology.
The Medical Research Commercialisation Fund invests in companies and startups in Australia and others.
The Medical Research Commercialisation Fund invests in companies and startups at Series A, Seed, Series B, Late Stage (Series C+).
The Medical Research Commercialisation Fund usually invests $1-5 m on average.
The Medical Research Commercialisation Fund can be reached through its website mrcf.com.au and its LinkedIn page. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for The Medical Research Commercialisation Fund — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query The Medical Research Commercialisation Fund directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 13 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.